Dr Sandy Primrose - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.

aProximateTM

Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Dr Sandy Primrose

Non-Executive Chair

Alongside his non-executive director (NXD) role at Newcells Biotech, Sandy Primrose is also NXD at Arquer Diagnostics and is actively engaged with a number of early-stage companies. Sandy is the senior partner at Business and Technology Management, a biotechnology and healthcare consultancy practice.

Previously, Sandy was an academic at Warwick University and then held posts as Senior Director of Drug Development at Searle Research and Development and then managed the Life Science business of Amersham International (now part of GE). After that he held senior management positions in a number of early-stage companies as well as serving on the board of the Microbiological Research Authority (a Special Health Authority) and then the Health Protection Agency.

Headshot of Sandy